CN114286823A - 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 - Google Patents
一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 Download PDFInfo
- Publication number
- CN114286823A CN114286823A CN202180002186.2A CN202180002186A CN114286823A CN 114286823 A CN114286823 A CN 114286823A CN 202180002186 A CN202180002186 A CN 202180002186A CN 114286823 A CN114286823 A CN 114286823A
- Authority
- CN
- China
- Prior art keywords
- compound
- clopidogrel
- formula
- derivative
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NTGRLKONMLOCIZ-UHFFFAOYSA-N 2,3,3a,4-tetrahydrothieno[3,2-b]pyridin-2-ol Chemical class N1C=CC=C2SC(O)CC21 NTGRLKONMLOCIZ-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- 208000007536 Thrombosis Diseases 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000003937 drug carrier Substances 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 24
- 229940125782 compound 2 Drugs 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 5
- 229940126214 compound 3 Drugs 0.000 claims description 5
- 125000005647 linker group Chemical group 0.000 claims description 5
- 208000005189 Embolism Diseases 0.000 claims description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 4
- 208000001435 Thromboembolism Diseases 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical class C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 abstract description 44
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 abstract description 40
- 229960003009 clopidogrel Drugs 0.000 abstract description 40
- 230000000740 bleeding effect Effects 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 22
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000001603 reducing effect Effects 0.000 abstract description 10
- 239000002207 metabolite Substances 0.000 abstract description 9
- 230000003073 embolic effect Effects 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 3
- 239000008280 blood Substances 0.000 abstract description 3
- 229940127218 antiplatelet drug Drugs 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 230000004044 response Effects 0.000 abstract description 2
- 101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 abstract 1
- 101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 abstract 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000000543 intermediate Substances 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 24
- 208000032843 Hemorrhage Diseases 0.000 description 22
- 208000034158 bleeding Diseases 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
- 238000012512 characterization method Methods 0.000 description 16
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- -1 clopidogrel derivative compounds Chemical class 0.000 description 14
- CWUDNVCEAAXNQA-AWGNNQSZSA-N (2z)-2-[1-[(1s)-1-(2-chlorophenyl)-2-methoxy-2-oxoethyl]-4-sulfanylpiperidin-3-ylidene]acetic acid Chemical compound N1([C@H](C(=O)OC)C=2C(=CC=CC=2)Cl)CCC(S)\C(=C/C(O)=O)C1 CWUDNVCEAAXNQA-AWGNNQSZSA-N 0.000 description 12
- 238000005160 1H NMR spectroscopy Methods 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 11
- 239000003208 petroleum Substances 0.000 description 10
- 239000007787 solid Substances 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 5
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000000702 anti-platelet effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 210000003363 arteriovenous anastomosis Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000007211 cardiovascular event Effects 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005465 B01AC22 - Prasugrel Substances 0.000 description 1
- ZILOPGNCTJNOEH-VWLOTQADSA-N CC(OC(C=CC=C1)=C1C(OCC(OC1=CC(CN(CC2)[C@H](C(OC)=O)C(C=CC=C3)=C3Cl)=C2S1)=O)=O)=O Chemical compound CC(OC(C=CC=C1)=C1C(OCC(OC1=CC(CN(CC2)[C@H](C(OC)=O)C(C=CC=C3)=C3Cl)=C2S1)=O)=O)=O ZILOPGNCTJNOEH-VWLOTQADSA-N 0.000 description 1
- KZXHGHRRNLZXAX-MHZLTWQESA-N CC1=C(C)N=C(COC(CCC(OC2=CC(CN(CC3)[C@H](C(OC)=O)C(C=CC=C4)=C4Cl)=C3S2)=O)=O)C(C)=N1 Chemical compound CC1=C(C)N=C(COC(CCC(OC2=CC(CN(CC3)[C@H](C(OC)=O)C(C=CC=C4)=C4Cl)=C3S2)=O)=O)C(C)=N1 KZXHGHRRNLZXAX-MHZLTWQESA-N 0.000 description 1
- 101710201076 Carboxylesterase 1 Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 101000938676 Homo sapiens Liver carboxylesterase 1 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102100030817 Liver carboxylesterase 1 Human genes 0.000 description 1
- 101100172720 Rattus norvegicus Ces1e gene Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 description 1
- 229960001667 alogliptin Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- JYWJULGYGOLCGW-UHFFFAOYSA-N chloromethyl chloroformate Chemical compound ClCOC(Cl)=O JYWJULGYGOLCGW-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- DCASRSISIKYPDD-UHFFFAOYSA-N clopidogrel carboxylic acid Chemical class C1CC=2SC=CC=2CN1C(C(=O)O)C1=CC=CC=C1Cl DCASRSISIKYPDD-UHFFFAOYSA-N 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 1
- 229960002465 dabrafenib Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 102000054098 human CES1 Human genes 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- DTGLZDAWLRGWQN-UHFFFAOYSA-N prasugrel Chemical compound C1CC=2SC(OC(=O)C)=CC=2CN1C(C=1C(=CC=CC=1)F)C(=O)C1CC1 DTGLZDAWLRGWQN-UHFFFAOYSA-N 0.000 description 1
- 229960004197 prasugrel Drugs 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种光学活性2‑羟基四氢噻吩并吡啶类衍生物,其具有如下式(I)的化合物或其药学上可接受的盐,或包含式(I)的化合物或其盐和药学上可接受的载体的药物组合物。将式(I)的化合物或其盐或其药物组合物,用于制备预防或治疗由血栓引起的栓塞性疾病药物中的应用。所述化合物能有效的改善药代动力学性质,提高了氯吡格雷活性代谢产物的生物利用度,活性代谢产物的生成量显著的高于氯吡格雷,有望实现通过显著降低药物剂量,在达到起效快和疗效高的同时,降低抗血小板聚集药物的出血等副作用。
Description
PCT国内申请,说明书已公开。
Claims (10)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2020107673737 | 2020-08-03 | ||
CN202010767373 | 2020-08-03 | ||
PCT/CN2021/109965 WO2022028347A1 (zh) | 2020-08-03 | 2021-08-02 | 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114286823A true CN114286823A (zh) | 2022-04-05 |
CN114286823B CN114286823B (zh) | 2023-11-28 |
Family
ID=80117006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180002186.2A Active CN114286823B (zh) | 2020-08-03 | 2021-08-02 | 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114286823B (zh) |
WO (1) | WO2022028347A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023134682A1 (zh) * | 2022-01-11 | 2023-07-20 | 天地恒一制药股份有限公司 | 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114736215B (zh) * | 2022-04-19 | 2023-04-11 | 中荣凯特(北京)生物科技有限公司 | 四氢噻吩并吡啶氘代衍生物及其制备方法和药物用途 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102863457A (zh) * | 2010-02-02 | 2013-01-09 | 江苏威凯尔医药科技有限公司 | 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途 |
CN103554132A (zh) * | 2013-10-31 | 2014-02-05 | 李纪宁 | 四氢噻吩并吡啶氘代衍生物及其制备方法和药物用途 |
CN103694250A (zh) * | 2012-09-28 | 2014-04-02 | 武汉启瑞药业有限公司 | 噻吩吡啶类衍生物及其制备方法和医药用途 |
CN105153192A (zh) * | 2014-09-02 | 2015-12-16 | 南京曼杰生物科技有限公司 | 取代的四氢噻吩并吡啶衍生物及其应用 |
CN107304215A (zh) * | 2016-04-20 | 2017-10-31 | 陕西合成药业股份有限公司 | 噻吩吡啶类衍生物及其制备方法和用途 |
CN114736215A (zh) * | 2022-04-19 | 2022-07-12 | 中荣凯特(北京)生物科技有限公司 | 四氢噻吩并吡啶氘代衍生物及其制备方法和药物用途 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
-
2021
- 2021-08-02 WO PCT/CN2021/109965 patent/WO2022028347A1/zh active Application Filing
- 2021-08-02 CN CN202180002186.2A patent/CN114286823B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102863457A (zh) * | 2010-02-02 | 2013-01-09 | 江苏威凯尔医药科技有限公司 | 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途 |
CN103694250A (zh) * | 2012-09-28 | 2014-04-02 | 武汉启瑞药业有限公司 | 噻吩吡啶类衍生物及其制备方法和医药用途 |
CN103554132A (zh) * | 2013-10-31 | 2014-02-05 | 李纪宁 | 四氢噻吩并吡啶氘代衍生物及其制备方法和药物用途 |
CN105153192A (zh) * | 2014-09-02 | 2015-12-16 | 南京曼杰生物科技有限公司 | 取代的四氢噻吩并吡啶衍生物及其应用 |
CN107304215A (zh) * | 2016-04-20 | 2017-10-31 | 陕西合成药业股份有限公司 | 噻吩吡啶类衍生物及其制备方法和用途 |
CN114736215A (zh) * | 2022-04-19 | 2022-07-12 | 中荣凯特(北京)生物科技有限公司 | 四氢噻吩并吡啶氘代衍生物及其制备方法和药物用途 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023134682A1 (zh) * | 2022-01-11 | 2023-07-20 | 天地恒一制药股份有限公司 | 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
WO2022028347A1 (zh) | 2022-02-10 |
CN114286823B (zh) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102863457B (zh) | 光学活性2-羟基四氢噻吩并吡啶衍生物及其制备方法与在制药中的用途 | |
CN114286823A (zh) | 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 | |
CN103554132B (zh) | 四氢噻吩并吡啶氘代衍生物及其制备方法和药物用途 | |
CN103052637A (zh) | 醛糖还原酶抑制剂及其用途 | |
EP0503471A1 (de) | Neue acylaminosubstituierte Hetrazepine | |
JP6290884B2 (ja) | c−FMSキナーゼ阻害剤の調製プロセス | |
CN104418891B (zh) | 水溶性2‑羟基四氢噻吩并吡啶衍生物的制备及其医药用途 | |
CN102351877B (zh) | 噻吩衍生物、其制备方法和用途 | |
JP2022538086A (ja) | Rockプロテインキナーゼ阻害薬としてのイソキノリンの誘導体及びその使用 | |
CN105367582B (zh) | 银杏内酯b衍生物及其在药物中的应用 | |
CN111440146A (zh) | 一种具有par4拮抗活性的苯并三嗪类化合物及其应用 | |
KR20000057418A (ko) | 벤조피라노피롤 및 벤조피라노피리딘 알파-1 아드레날린성화합물 | |
CN111166745A (zh) | 含消旋氧吡格雷或其盐的组合物及应用 | |
CN111150731A (zh) | 含氧吡格雷光学异构体或其盐的组合物及应用 | |
JP2022062193A (ja) | 不飽和脂肪族オレフィン性結合を含有するチエノピリジン誘導体、その調製方法および使用 | |
CN102260239B (zh) | 胡黄连素衍生物及其制备与应用 | |
JP2024505709A (ja) | フェニルジヒドロピリミジン系化合物及びその使用 | |
CN111747960A (zh) | 一种取代吡唑[3,4-d]嘧啶类化合物及其制备方法和应用 | |
JPS637549B2 (zh) | ||
CN115141169B (zh) | 一种萜内酯衍生物及其在医药上的应用 | |
CN114213381B (zh) | 4-色满酮衍生物及其制备方法和医药用途 | |
CN116744921A (zh) | 一种光学活性2-羟基四氢噻吩并吡啶类衍生物及其制备方法和用途 | |
CN110396098B (zh) | 银杏内酯b氮杂环衍生物及其盐的制备及药用用途 | |
CN88103236A (zh) | 强心剂三环唑酮及其制备方法 | |
JP3049284B2 (ja) | ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: An optically active 2-hydroxytetrahydrothiophene pyridine derivative and its preparation method and application Granted publication date: 20231128 Pledgee: Hunan Caixin technology microfinance Co.,Ltd. Pledgor: TIANDI HENGYI PHARMACEUTICAL Co.,Ltd. Registration number: Y2024980012026 |